Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Pharming Group N.V.NASDAQ: PHAR

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $2.58M a year earlier. Trailing-twelve-month stock-based compensation was $3.48M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 3.8 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $869K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$3.48M-33.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.4% is the lowest of 9, against a peer median of -2.2%.
  • Stock-based compensation amounts to 0.9% of revenue for PHAR, versus a peer median of 16.8%.
PHAR Competitors
Stock-Based Compensation for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$172.73B USD+92559.3%-2.6%16.8%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M USD+2.8%+19.1%220.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M USD+4.4%+10.1%13.8%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$121.89M USD+50.0%+23.9%13.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M USD-20.0%+6.1%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$26.2M USD-9.4%+12.2%81.7%
PHVSPharvaris N.V.LTM Sep 2026€17.97M EUR-7.1%+18.8%—
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
PHARPharming Group N.V.LTM Mar 2026$3.48M USD-33.4%—0.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
Peer median (excluding PHAR) —-2.2%+11.1%16.8%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.